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Background: An early step of advanced ovarian cancer begins when floating cancerous cells as single cells or small
clusters grow on the peritoneal surface. This surface is rich in extracellular matrix (ECM) proteins, which have
profound effects on cellular behaviour and can facilitate cancer progression. Subsequently, this ECM may alter
cellular metabolism making cancer cells susceptible to chemotherapeutic agents differently. Therefore, generating a
cell culture tool in vitro that includes the interaction between ECM and cancer cells will facilitate our understanding
of how cancer cells behave during cancer treatment. There is some evidence to suggest that in an in vitro model
that includes ECM components such as collagens will provide a better predictive tool for drug evaluation than a
traditional cell monolayer (2D) culture model.
Findings: As a proof -of- concept, we made a collagen gel in a 96-well plate format and utilised this to evaluate
the efficacy of clinical cytotoxic drugs, a targeted drug, and food compounds in single and combination treatments.
The primary endpoints were to measure the reduction of cellular metabolism and secretion of vascular endothelial
growth factor (VEGF). The invasive capacity of cancer cells was observed in collagen gels and it was cell line-dependent.
The responses to drugs were prominently observed in collagen gels, but they had little effect on 2D cell monolayers.
These responses were cell line- and type of drug-dependent.
Conclusions: The collagen gel in a 96 well plate format was easy to set up and could have potential to identify drug
sensitivity in the clinical management of women with platinum resistant ovarian cancer.
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Ovarian cancer is the fourth most common cause of
cancer related death for women in the developed world.
It is usually advanced at diagnosis and chemotherapy
normally prolongs life but is not curative. The high mor-
tality of ovarian cancer is largely explained by the fact
that patients present with widely metastatic disease
within the peritoneal cavity [1]. Although most ovarian
cancer initially responds well to the current front line
cytotoxic agents, chemo-resistant recurrent disease com-
monly evolves and is usually fatal. Treatment is further
complicated by the high degree of patient-to-patient* Correspondence: kenny.chitcholtan@otago.ac.nz
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creativecommons.org/publicdomain/zero/1.0/tumour heterogeneity. Consequently, there is an urgent
need for new therapeutic strategies and methods to en-
able variations in responses by distinct tumours to drugs
to be studied. Further, the ability to study the effects of
drug combinations, such as cytotoxic agents and other
anticancer drugs (targeted agents or bioactive food com-
pounds) has not been fully evaluated in ovarian cancer.
To advance these goals, pre-drug screening tools that
take account of some aspects of the tumour microenvir-
onment should be developed.
Advanced ovarian cancer cells preferentially adhere
and grow on top of the mesothelial lining of abdominal
cavity (peritoneum). The peritoneum is rich in extracellu-
lar matrix (ECM) proteins, which offers a favourable at-
tachment site for cancer cells that facilitates survival and
metastatic invasion [2]. Therefore, we develop a gel-based
method in which cells may invade a microenvironmenticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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to grow in a three dimension (3D) following invasion is
provided. Many studies have reported recently that cancer
cells cultured in cell monolayer (2D) and 3D models show
distinctive patterns of behaviour due to differential gene
and protein expressions [3–5]. The imbalance of drug de-
velopment and clinical selection may be attributed partly
to limitations in the understanding of the underlying bio-
logical processes and the lack of suitable assays. We inves-
tigate the concept that an assay method that incorporates
a 3D component is practical. The bedside problems are il-
lustrated, for example, by patients with platinum resistant
ovarian cancer. There are already many therapeutic op-
tions, and this choice is increasing at a rapid pace, but for
these patients’ response rates to individual drugs is likely
to be low. We, therefore, aim to introduce a framework
for a clinically useful in vitro sensitivity assay that may
have potential to avoid the necessity of trialing toxic or ex-
pensive drugs in patients who may not respond.
In this study, we selected drugs on the basis of current
clinical discussions. Cytotoxic agents including paclitaxel
and carboplatin are widely used to treat ovarian cancers.
Targeted agents show promising results in other types of
tumours, but there is a limited clinical data for ovarian
cancer. Ovarian cancer cells show a dysregulation of PI-
3 K/Akt/mTOR pathway. Therefore, an agent that spe-
cifically compromises these pathways is of great interest.
Everolimus has been reported to show antitumour activ-
ity in pre-clinical tumour xenografts in mice [6]. Resver-
atrol and (−)-epigallocatechin-3-gallate (EGCG) are
bioactive natural food compounds, and they have been
reported to exhibit anti-tumour activities in in vitro and
in vivo animal models [7, 8]. However, the use of resver-
atrol and EGCG as potential therapeutic agents for can-
cer treatment in a proper randomised clinical trial is
still undetermined.
To approximate the microenvironment of an early
growth stage of metastatic ovarian cancer cells at the
peritoneal membrane, we have developed a collagen gel
model in a 96 well plate format and culture ovarian can-
cer cells on top of the collagen gel. Cellular metabolism
as an indication of cell viability and the production of
secreted VEGF are the primary endpoints after treat-
ment with selective cytotoxic drugs, a targeted agent and
active food compounds. As a comparison, assays were
also performed on cells cultured in similar conditions in
a 2D monolayer.
Materials and methods
The human ovarian adenocarcinoma cell lines, SKOV-3
and OVCAR-5, were obtained from Dr Judith McKenzie,
Haematology Research group, University of Otago,
Christchurch, New Zealand. SKOV-3 and OVCAR-5
cells were maintained in MEM and DMEM medium,respectively (GIBCO®, Life Technologies, New Zealand)
supplemented with 10 % fetal bovine serum (FBS)
(GIBCO®, Life Technologies, New Zealand), PenStrep
(GIBCO®, Life Technologies, New Zealand) at a working
concentration of 100 units/ml penicillin and 100 μg/ml
streptomycin, 2 mM glutaMAX™ (GIBCO®, Life Tech-
nologies, New Zealand), and 2 μg/ml Fungizone® (Life
Technologies, New Zealand). The final concentration
of glucose in the media is 5.5 mM. The supple-
mented media is henceforth referred to as working
media. SKOV-3 and OVCAR-5 cells in the working
media were maintained at 37 °C in a humidified 5 % CO2
atmosphere.Generation of cell culture using collagen I and Geltrex™
and 2D cell monolayers in a 96-well plate
Partly confluent cell monolayers of SKOV-3 and
OVCAR-5 were washed with PBS pH 7.4 and incubated
with 1X trypsin-EDTA (Life Technologies, New Zealand)
for 20–30 min. Cells were collected by a centrifugation
at 300 g for 5 min. The cultures of ovarian cancer cells
on top of collagen gels are previously described [9, 10].
Briefly, cell pellets were re-suspended in the working
media and cell counts was obtained with a haemocytom-
eter. A 96-well plate was overlaid with 60 μl mixture of
cold collagen I (1 mg/ml, Sigma, New Zealand) and
Geltrex™ (2.5 mg/ml, Life Technologies, New Zealand)
solution and allowed to polymerise at 37 °C in a hu-
midified 5 % CO2 atmosphere for 30 min. Cells (5000
cells in final volume of 200 μl working media) were
added to each well and allowed to grow on top of poly-
merised collagens for 6 days with replacement of fresh
media every 2 days. For cell monolayers, cell numbers
and culture condition were similar to the 3D culture
except non coated 96-well plates were used.Fluorescent image of cells cultured on top and inside
collagen gels
For cells on top of collagen gels
The mixture of collagen solution (200 μl) was added to a
48 well plate and allowed to polymerise at the similar
condition as described above. Single cell suspension
(100,000 cells) were added onto the polymerised colla-
gen gel and cultured for 6 days with replacement of
fresh media every 2 days. Cells grown on top of collagen
gel were fixed with 4 % paraformaldehyde in PBS pH 7.4
for 60 min and then washed extensively with PBS pH 7.4.
Cells were then stained with Texas Red-Phalloidin
(Molecular Probe, Life Technology) overnight at 4 °C
and followed the staining with 10 ug/ml Hoechst
33492 (Molecular Probe, Life Technology) for 20 min.
Cells were washed extensive with ice cold PBS pH 7.4
plus 0.1 % Tween-20.
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A round coverslip (20 mm diameter, ProSciTech,
Australia) was overlaid with 150 μl cold mixture of colla-
gen type I and Geltrex™ at final concentrations 1 mg/ml
and 2.5 mg/ml, respectively. Gels were allowed to poly-
merise at 37 °C in a humidified 5 % CO2 atmosphere for
20 min. Cells (100,000) were mixed with 100 μl cold col-
lagen solution and added on the top of first polymerised
collagen gel. The gels were allowed to polymerise at 37 °
C in a humidified 5 % CO2 atmosphere for 20 min.
Cover slips were then carefully placed in 12-well culture
plate and 1.5 ml working media. Cells were maintained
in this condition for 6 days with replacement of fresh
media every 2 days. Cells inside collagen gels were fixed
with −20 °C acetone:methanol (50 %:50 % vol:vol) for
20 min at 4 °C. Cells were washed with PBS pH 7.4 four
times for 10 min each washing. Cells were blocked with
4 % BSA and incubated with anti-actin antibody (Santa
Cruz, Biotechnology Inc, USA) overnight at 4 °C. Cells
were then washed four times for 10 min each washing
and incubated with a 1/500 dilution of a secondary anti-
body conjugated with FITC for 90 min at 37 °C. Cells
were then stained with 10 μg/ml Hoechst 333492 for
30 min at 37 °C. Cells were washed extensively with ice
cold PBS pH 7.4.
Prior to imaging with the epifluorescent microscope,
anti-fading solution (Daka Fluorescent Mounting
Medium) was applied to prevent photo bleaching. Fluor-
escent images were captured by using the epifluorescent
microscope (AxioVersion 4.5. Apotome software, Carl
Ziess) EC plan-Neofluar 20x and 40x/1.30 Oil Dic M27
objective, with DAPI, FITC, and Texas Red filters. For
Z-stack images, 0.5 μm thicknesses of Z-axis planes were
taken and the 3D images were generated and analysed.
Drug treatment
As shown in Fig. 1a, at day 6 (as indicated arrow) the
total volume of media in each well was 200 μl. Prior to
the addition of fresh media supplemented with active
compounds, 100 μl of media were removed from each
well, and 100 μl of fresh media containing active com-
pounds at concentrations of 10 μM resveratrol, 10 μM
EGCG, 0.2 μM paclitaxel, 2 μM Everolimus, and 20 μM
cisplatin were added. Therefore, the final concentrations
of active compounds were 5 μM for resveratrol and
EGCG, 0.1 μM for paclitaxel, 10 μM cisplatin, and 1 μM
everolimus, Again at day 8 and day 10 (as indicated
arrow), 100 μl of cell media were removed from each
well and 100 μl of fresh media containing 5, 0.1, 10,
1 μM of resveratrol and EGCG, paclitaxel, cisplatin, and
everolimus were added, respectively. Alamar Blue dye
solution (20 μl) was added to each well on day 11 and
incubated with cells for 24 h before analysis on day 12.
The absorbance at each well of the 96-well plate wasread at 560 and 600 nm using a microplate reader (Var-
ioskan Flash®, Thermo Scientific)). The stock solutions
of paclitaxel (Sigma, New Zealand), cisplatin (Sigma,
New Zealand), and everolimus (LC Laboratories, MA,
USA) were made in 100 % dimethyl sulfoxide (DMSO).
Resveratrol (Sigma, New Zealand) stock solution was
made in 50 % DMSO: 50 % PBS pH 7.4. The stock solu-
tion of EGCG (Sigma, New Zealand) was dissolved in
PBS pH 7.4. Controls incubations contained similar con-
centration to that of DMSO in the highest dose of
treated samples.
ELISA of vascular endothelial growth factor (VEGF)
ELISA of VEGF was performed using the DuoSet Human
VEGF ELISA Kit (R&D System) that detectsVEGF-A iso-
forms. Cell media from at least four independent experi-
ments were collected and analysed for VEGF.
Statistical analysis
Cellular metabolism was calculated from the difference
of absorbance at 600 and 570 nm. Data represented at
least four independent experiments. The mean and
standard error were reported and significant changes
(p < 0.05) were determined by student’s t-tests.
Results
As shown in Fig. 1a, we cultured ovarian cancer cell
lines, SKOV-3 and OVCAR-5, on the top of polymerised
collagen gel for 6 days prior to challenging them with
cytotoxic drugs (paclitaxel and cisplatin), a targeted drug
(everolimus) and food compounds (resveratrol and
EGCG). As indicated in Fig. 1b, after six days of culture,
OVCAR-5 cell line (Fig. 1b-a) grew on top of the colla-
gen gel and formed a compact sheet, and small compact
colonies (data not shown) were also observed. The stain-
ing of actin was restricted to the region of cell-cell con-
tacts. At the protrusive front of OVCAR-5, the cell sheet
exhibited a lack of filopodia formation suggesting the
cells were not competent to invade the collagen gel. On
the other hand, actin filaments were observed at the
leading edge of SKOV-3 cells. There were notable for-
mations of filopodia (arrow Fig. 1b-b) and the accumula-
tion of actin bundles of cells at the leading front (arrow
head Fig. 1b-b). Occasionally, there were some invasive
SKOV-3 cells observed below the surface of the gel
(Fig. 1b-c). These invasive SKOV-3 cells displayed an
elongated morphological appearance similar to mesen-
chymal morphology (Fig. 1b-c, arrows). On the con-
trary, OVCAR-5 cell line grew only on the top of
collagen gel surface without any sign of invasion. Our
result using OVCAR-5 was consistent with a previous
observation [11].
To further confirm that the cell lines have different in-
vasive capacity when they were exposed to collagen gels,
Fig. 1 Experimental setup and growth of ovarian cancer cells cultured on top of collagen gels in a 96-well plate. a. Two cell lines, SKOV-3 and
OVCAR-5, were cultured on the top of collagen gel overlaid 96 well plates for 6 days and treatment with active compounds for 6 days. On day
11, Alamar blue was added for overnight and the change of colour as the indication of cellular metabolism was examined on day 12. b OVCAR-5
cells grew on top of the gel as a compact sheet without the projection of filopodia suggesting this cell line is non invasive cancer cells (a). SKOV-
3 cells showed the formation of filopodia at the invasive front of cells (b, arrow) and there was an appearance of actin bundles accumulation of
invasive cells (b, arrow head). The invasive SKOV-3 cells displayed mesenchylmal morphological appearance (c, arrows). Red is actin staining and
blue is the nucleus
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inside collagen gels and allowed them to grow for 6 days.
Again a difference was observed. OVCAR-5 cell line
grew as compact spherical colonies without the migra-
tion of cells at the edge of the colony (Fig. 2a). In con-
trast, SKOV3 cell line at the rim of the colony exhibited
an invasive characteristic by producing projection of filo-
podia (Fig. 2b).Next, we determined the efficacy of single drug and
combination treatments in cell monolayers and cells on
top of collagen gels. Single and combination treatments
were selectively affected in OVCAR-5 cells in collagen
gel (Figs. 3 and 4). Single treatments that reduced cellu-
lar metabolism only in collagen gel compared to the
control included resveratrol (29 %, Fig. 3a), EGCG (35 %,
Fig. 3a), and paclitaxel (28.1 %, Fig. 3b). Everolimus
Fig. 2 Morphological characteristics of OVCAR-5 and SKOV-3 cultured inside the collagen gel. OVCAR-5 formed spherical colony without
the invasive capability when it cultured inside collagen gels (a) but the colony of SKOV-3 showed invasive capacity at the edge of colony
that produced the intrusion of the plasma membrane, indicating invasive behaviour (b). Actin staining was shown in green and the
nucleus was shown in blue
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layers (13 %) and collagen gel (16 %). The cell monolayers
of OVCAR-5 cell line did not show any marked reduction
of cellular metabolism except cisplatin (12 %, Fig. 3c).
The combinatory treatments were selectively affected
in collagen gel OVCAR-5 cells. We categorised the ac-
tion of these drugs into three modes of action. First, the
combinations that exerted a marked reduction of cellu-
lar metabolism only in collagen gels included resvera-
trol + EGCG (22.2 %, Fig. 3a), resveratrol + cisplatinFig. 3 Cellular metabolism profiles of OVCAR-5 cell line with single and co
(b), resveratrol + cisplatin (c), resveratrol + everolimus (d) in 2D cell monola
cell monolayers and 3D ECM was the relative value to the control. The stat
(*P < 0.05, student’s t-test) and 3D ECM (#P < 0.05, student’s t-test) was compa
least four independent experiments with triplicate(23 %, Fig. 3c), resveratrol + everolimus (21 %, Fig. 3d),
EGCG+ paclitaxel (29 %, Fig. 4a), and EGCG+ everolimus
(20 %, Fig. 4c). Second, the combination that showed anti-
metabolic activity in both 2D monolayers (20.4 %) and
collagen gels (20 %) was only resveratrol + paclitaxel
(Fig. 3b). Third, the combinations that did not show any
reductions in either monolayers or collagen gels were
EGCG+ cisplatin (Fig. 4b), paclitaxel + cisplatin (Fig. 4d),
paclitaxel + everolimus (Fig. 4e) and cisplatin + everolimus
(Fig. 4f). There was no additive or synergistic inhibition inmbination treatment of resveratrol + EGCG (a), resveratrol + paclitaxel
yers (black bar) and 3D ECM (grey bar). The representative graph in 2D
istical difference of single and combination in 2D cell monolayers
red between the control and treated cells. Data was obtained from at
Fig. 4 Cellular metabolism profiles of OVCAR-5 cell line with single and combination treatment of EGCG + paclitaxel (a), EGCG + cisplatin (b),
EGCG + everolimus (c), paclitaxel + cisplatin (d) paclitaxel + everolimus (e) and cisplatin + everolimus (f) in 2D cell monolayers (black bar) and 3D
ECM (grey bar). The representative graph in 2D cell monolayers and 3D ECM was the relative value to the control. The statistical difference of
single and combination in 2D cell monolayers (*P < 0.05, student’s t-test) and 3D ECM (#P < 0.05, student’s t-test) was compared between the
control and treated cells. Data was obtained from at least four independent experiments with triplicate
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layers showed limited response to single and combination
treatments.
The mono- and bi-combinatorial approaches of com-
pounds were also conducted in cell monolayers and colla-
gen gels of SKOV-3 cell line. First, the single treatments
that significantly reduced cell metabolism only in collagen
gels included EGCG (17 %, Fig. 5a) and cisplatin (23 %,Fig. 5c). Second, single treatments that reduced cellular
metabolism in both cell monolayers and collagen gels
were paclitaxel (36 % cell monolayers vs 30 % collagen,
Fig. 5b) and everolimus (22 % cell monolayers vs 20 %
collagen, Fig. 5d). Third, the combinations that reduced
cellular metabolism only in collagen gels included res-
veratrol + EGCG (21 %, Fig. 5a), resveratrol + paclitaxel
(25 %, Fig. 5b), resveratrol + cisplatin (31 %, Fig. 5c),
Fig. 5 Cellular metabolism profiles of SKOV-3 cell line with single and combination treatment of resveratrol + EGCG (a), resveratrol + paclitaxel (b),
resveratrol + cisplatin (c), resveratrol + everolimus (d) in 2D cell monolayers (black bar) and 3D ECM (grey bar). The representative graph in 2D cell
monolayers and 3D ECM was the relative value to the control. The statistical difference of single and combination in 2D cell monolayers
(*P < 0.05, student’s t-test) and 3D ECM (#P < 0.05, student’s t-test) was compared between the control and treated cells. Data was obtained from at
least four independent experiments with triplicate
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platin (34 %, Fig. 6b), and EGCG + everolimus (17 %,
Fig. 6c). Finally, the combinations that reduced cell me-
tabolisms in both cell monolayers and collagen gels in-
cluded EGCG + paclitaxel (26 % cell monolayers vs 31 %
collagen, Fig. 6a), paclitaxel + cisplatin (34 % cell mono-
layers vs 61 % collagen, Fig. 6d), paclitaxel + everolimus
(28 % cell monolayers vs 33 % collagen, Fig. 6e), and cis-
platin + everolimus (24 % cell monolayers vs 33 % colla-
gen, Fig. 6f ). Again, there was a lack of additive and
synergistic inhibition of cellular metabolism in the com-
bination treatments of SKOV-3 line.
Next, we evaluated the production of secreted VEGF in
the cell media after drug treatments. Single treatment of
OVCAR-5 cell monolayers with cisplatin significantly in-
creased the secreted VEGF (1.8 ng/ml control vs 3 ng/ml
cisplatin, Fig. 7a). The combination of everolimus with
paclitaxel (Fig. 7c) and cisplatin (Fig. 7d) reduced the
VEGF secretion in both 2D cell monolayers and collagen
gels. These combinations were also reproducible in
SKOV-3 cell line (Fig. 7e, f ). However, in SKOV-3 line the
combination of everolimus with paclitaxel and cisplatin
produced a greater significant reduction in collagen gels
than 2D cell monolayers. Other combinations did not
change the VEGF secretion in cell monolayers and colla-
gen gels in both cell lines (data not shown).Discussion
We present a simple reproducible a 96-well collagen gel
model for cell culture. The system is easy to set up, in-
expensive, quick to perform, and suitable for high-
throughput screening. The model provides an environ-
ment closely comparable to those experienced by ovarian
cancer cells on the peritoneal membrane surface and the
composition of the gel in our study is constituted to partly
replicate the properties of the membrane. The model,
therefore, enables us to study cell growth, survival, re-
sponsiveness to anti-cancer drugs and invasive character-
istics at the early stage of tumorigenic progression at the
peritoneal membrane lining.
The 96-well format may provide a convenient platform
as a pre-clinical drug screening tool and for exploring
biological pathways, which has not been reported previ-
ously for ovarian cancer. This system revealed that cells
exhibit different drug sensitivities when cultured on
traditional 2D monolayers or on the collagen gels and
thus confirmed that the environments elicit distinct be-
haviours. Our project has not yet determined the influ-
ence of different gel compositions on ovarian cancer cell
characteristics. We have used a murine collagen in this
preparation, but the difference from human collagen is
small as collagens are highly conservative proteins in
vertebrates [12, 13] and the murine collagen is a well-
Fig. 6 Cellular metabolism profiles of SKOV-3 cell line with single and combination treatment of EGCG + paclitaxel (a), EGCG + cisplatin (b), EGCG
+ everolimus (c), paclitaxel + cisplatin (d), paclitaxel + everolimus (e) and cisplatin + everolimus (f) in 2D cell monolayers (black bar) and 3D ECM
(grey bar). The representative graph in 2D cell monolayers and 3D ECM was the relative value to the control. The statistical difference of single
and combination in 2D cell monolayers (*P < 0.05, student’s t-test) and 3D ECM (#P < 0.05, student’s t-test) was compared between the control and
treated cells. Data was obtained from at least four independent experiments with triplicate
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The compositions of ECM used in our study are closely
similar to those present in the human peritoneal mem-
brane surface [15]. The concentrations of collagen I, IV
and laminins in our collagen model are consistent with
previous studies [16, 17]. It is increasingly recognised that
the different compositions and concentrations of ECM
can contribute to the invasive phenotypes of cancer cells
as previously described [17]. Our study does not yet deter-
mine the influence of various concentrations of collagenson an invasive phenotype of ovarian cancer cells; an in-
creased stiffness of collagen compositions mimicking the
interstitial collagen components has reported to facilitate
invasive behaviour in breast cancer cells [17].
Drugs chosen in our study are categorised into cyto-
toxic agents (paclitaxel and cisplatin), targeted agent
(everolimus) and bioactive food compounds (resveratrol
and EGCG). The concentration of each compound was
selected based on their bioavailability in plasma of
humans. In cancer patients, the average peak plasma
Fig. 7 Production of secreted vascular endothelial growth factor (VEGF) of OVCAR-5 (a, b, c, and d) and SKOV-3 cells (e and f) in 2D cell monolayers
(black bar) and 3D ECM (grey bar). The statistical difference of single and combination in 2D cell monolayers (*P < 0.05, student’s t-test) and 3D ECM
(#P < 0.05, student’s t-test) was compared between the control and treated cells. The statistical difference of between 2D cell monolayers and 3D ECM
are donated ** (P < 0.05, student’s t-test). Data was obtained from at least four independent experiments with triplicate
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ranged from 0.23-0.43 μM [18]. Cisplatin plasma con-
centration is about 2.6 μM in cancer patients after one
hour IV [19]. Peak concentration of everolimus is ap-
proximately 0.1-5 μM [20]. After ingestion of 5 grams
resveratrol and 1.6 grams of EGCG, the peak plasma
concentration of native compounds after one hourreached approximately 5 μM and 7.4 μM, respectively
[21]. Our results indicate the effect on cellular metabol-
ism is drug- and cell culture format- dependent. Cells in
2D monolayers of OVCAR-5 and SKOV-3 show limited
responses to single and combination drug treatments
compared to collagen gels. In collagen gel model, there
are six drug combinations that show a significant
Hogg et al. Journal of Ovarian Research  (2015) 8:43 Page 10 of 12reduction of cell metabolism in OVCAR-5 line and ten
drug combinations exhibit anti-metabolism in SKOV-3
line. Our study shows that the bi-combinatory drug ap-
proach does not have any additive or synergistic effect
in comparison with the mono-treatment. The possible
explanations for this unresponsiveness to the drug com-
binations would be the antagonistic interaction of drug
combination that has been previously reported [22].
More importantly, the sequence of drug treatment may
play an important role in additive/synergistic effects. Se-
quential anticancer drug administration is currently
recognised as an important factor in cancer treatment
[23]. In our study, both drugs are mixed at the begin-
ning of treatment. In the clinic, co-administration of
cisplatin and paclitaxel is introduced every three weeks
for total of six cycles. A targeted drug including everoli-
mus is normally used as adjuvant regimen. For our fu-
ture study, we wish to use collagen gel model of ovarian
cancer cells to investigate the various sequences of ex-
perimental drug combinations and then validate these
combinations in an animal model.
Paclitaxel and cisplatin are cytotoxic drugs and com-
monly used in first-line treatment in women with ad-
vanced ovarian cancer. Paclitaxel is a tubulin stabilising
agent that inhibits cancer cell division in the G2/M
phase of the cell cycle and cell motility [24]. Our results
show a greater reduction of cell metabolism in paclitaxel
treated OVCAR-5 in collagen gel than cell monolayers.
This may suggest that tubulin expression of cancer cells
may be higher in collagen gels than cell monolayers.
Proteomic analysis of liver cancer cells maintained in
collagen gels reveals the increased level of several cyto-
skeletal associated proteins including tubulin [25].
Therefore, compromising cytoskeletal structure of can-
cer cells in collagen gel can produce a profound effect
on cell viability. Cisplatin is a platinum based compound
that crosses links with DNA and triggers apoptosis [26].
Platinum resistant ovarian cancer cells are highly preva-
lent, and the molecular basis of the resistance is attrib-
uted to several factors [27]. Both OVCAR-5 and SKOV-
3 have been previously reported to be cisplatin resistant
cell lines [28, 29]. Cisplatin has little effect on OVCAR-5
cells on collagen gel but shows a marginal inhibition in
cell monolayers. On the contrary, cisplatin reduces cellu-
lar metabolism of SKOV-3 in the collagen gel model but
not in cell monolayers. Therefore, responsiveness to cis-
platin observed in our study is cell culture format- and
cell type- dependent. Everolimus is a targeted drug that
specifically inhibits the function of mammalian target of
rapamycin (mTOR) pathway, which is dysfunctional in a
subset of ovarian cancers and is associated with the up
regulation of PTEN protein mutation and PI-3 K hyper-
activation [30]. A previous study showed everolimus ex-
hibits an anti-proliferative effect in cell monolayers andin in vivo animal model [6]. Our results show everolimus
equally affects cell metabolisms in both cell monolayers
and collagen gel model. The responsiveness of ovarian
cancer cells on collagen gel to cytotoxic and targeted
agents observed in this present study is consistent with
other types of cancers in 3D models. For example, breast
cancer cells are more sensitive to Her-2 and MEK inhib-
itors in 3D ECM than 2D cell monolayers [14, 31].
Our data show that physiological doses (5 μM) of res-
veratrol and EGCG can reduce cellular metabolism in
collagen gels but not in cell monolayers. The field of re-
search of resveratrol and EGCG and their potential anti-
cancer properties in vitro has been active for decades.
Resveratrol and EGCG are from grape and green tea, re-
spectively, and are well known to display an array of
anti-tumour activities in various types of cancer cell lines
including ovarian cancer, but knowledge of their anti-
tumour activities in ovarian cancer in vivo is very limited
[32]. In addition, most of available studies of resveratrol
and EGCG have been using non-physiological doses
(50–100 μM) in cell monolayers. These high doses are
not reached in plasma of animal models and human.
This may raise a question of the suitability of cell mono-
layers for a pre-clinical drug screening and exploring
biochemical pathways for cancer research because it is
uncertain whether the drug efficacy produced in 2D cell
monolayers is a true response. One possible explanation
for high levels of resveratrol and EGCG being necessary
in 2D cell monolayers is that the alteration of protein
expression, which responds to such active compounds,
may be insufficient in cell monolayers to detect readily,
and therefore high doses are required to produce an ob-
servable effect. On the other hand, those protein expres-
sions and functions may be fully optimised in a collagen
gel and, therefore a lower amount of active compounds
is needed to produce a similar significant effect.
It is important to note that the present study shows
the invasive capacity of ovarian cancer cells on collagen
gels, and also the invasion is notable when cells are in-
side the collagen gel and is cell line-dependent. SKOV-3
cell line has high expression of EGFR, Her-2, and c-Met
proteins and negative E-cadherin [33, 34]. Our results
are consistent with a previous study [35] suggesting
SKOV-3 cell line exhibits invasive capacity when cultur-
ing on the top or within collagen gels. SKOV-3 cells
shows aggressive growth, metastasis, and invasion in a
mouse model [36]. OVCAR-5 cell line has low expres-
sion of EGFR and Her-2 but high expression of c-Met
and E-cadherin [37]. Our results show that OVCAR-5
cell line does not display invasive capacity in collagen
gels, suggesting EGFR/Her-2 oncogenic expression may
be a primary factor in the aggressiveness of tumour inva-
sion in 3D gels [38]. Over expression of EGFR and
Her-2 correlate with invasive colorectal cancer cells in
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apart from 2D cell monolayers to assess invasive pheno-
types of ovarian cancer cells. Therefore, our collagen gel
model will be the forefront of biological tool that may
provide a mean of rapid assessment of oncogenic mol-
ecule alteration that facilitates invasive potential in a
subset of patients with advanced disease. This may lead
us to devise tailored treatment based on the invasive
characteristic of patient’s cancer cells. There are few re-
ports studying the growth property of ovarian cancer
cells in 3D collagen gel, but these studies have cultured
ovarian cancer cell lines within a collagen gel or a syn-
thetic matrix as a representative of in vivo primary and
secondary growing tumour [40, 41]. Our system is, how-
ever, designed to replicate the early growth stage of at-
tached and invasive ovarian cancer cells to the surface of
the peritoneal membrane where cancer cells are not yet
fully established secondary tumour nodules.
It is well known that secretion of VEGF is strongly
stimulated by tumour micro-environmental conditions
including hypoxia, an elevated expression of oncogenic
proteins, and stress- induced treatment. All these modu-
lators are observed in cancer patients. In our study, we
could rule out hypoxic induced effects because the level
of VEGF secreted from cells monolayers and collagen
gels is not significantly different. However, the stress-
related VEGF production induced by drugs may be pos-
sible. Even though the increase of VEGF in collagen gels
is not significant compared to the control but the ele-
vated VEGF is more pronounced in 2D cell monolayers
than collagen gels with cisplatin treatment. It is worthy
to note that paclitaxel and everolimus increase VEGF in
2D cell monolayers but not in collagen gels. It is unclear
how collagen matrix can influence the production of an-
giogenic proteins altered by anti-cancer agents. Again, it
is difficult to pinpoint the exact modulator that can
influence VEGF responses in our study, but results may
indicate that the production of VEGF in 2D cell mono-
layers and collagen gels is modulated by drugs in a dif-
ferent manner.
In summary, we demonstrated that ovarian cancer
cells on the collagen gel in a 96-well format can be used
to evaluate the cytotoxicity of anti-cancer drugs on
growth of ovarian cancer cells and to study an invasive
phenotype of ovarian cancer cells in a pre-clinical set-
ting. The collagen gel model provides an approximate
physiological microenvironment in which to study the
early attachment of metastatic growth of ovarian cancer
cells at the peritoneal membrane. The analysis of cellular
metabolism in individual ovarian cancer cell lines acted
as a preliminary guide to the cytotoxicity of anticancer
agents. In a clinical setting, each patient tumour will
have a distinct molecular background, and this collagen
gel model may have potential to provide an importantpreclinical tool for patient related drug screening, for
example to identify tumours with platinum resistant
disease.
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